COMMUNIQUÉS West-GlobeNewswire

Biomea Fusion to Become a Diabetes & Obesity Medicines Company
13/01/2025
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchise Biomea preparing icovamenib for late-stage clinical development 2025 corporate update to be presented at the 43 rd [...]
New Standard for Medtech Alternate Equipment Management (AEM)
13/01/2025
AAMI Document Clarifies Repair Requirements Arlington, VA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Alternate equipment management (AEM) plans for medical devices can create friction between original equipment manufacturers ( [...]
Novo Nordisk A/S - share repurchase programme
13/01/2025
Bagsværd, Denmark, 13 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]
OneMedNet Regains Compliance with NASDAQ Listing Requirements
13/01/2025
MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World [...]
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
13/01/2025
TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with [...]
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
12/01/2025
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year 1 Strong and Growing Demand for Galafold ® and Pombiliti ® + Opfolda ® Total Revenue Growth of 17-24% at CER Expected in 2025 >3,000 [...]
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
12/01/2025
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn [...]
Mereo BioPharma Provides Update on Lead Clinical Programs
12/01/2025
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive [...]
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
12/01/2025
Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89 million 2025 [...]
Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine
12/01/2025
-- One year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix SEATTLE, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately- [...]
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance
12/01/2025
ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
12/01/2025
Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024 Preliminary unaudited product revenue for the full- [...]
Lipozem: Introducing Lipozem as the Bizarre Turmeric Hack for Weight Loss Support
12/01/2025
LAKELAND, Fla., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Lipozem emerges in an era where weight management solutions seem endless—from strict diets to high-intensity workouts—yet one groundbreaking discovery is rapidly gaining [...]
iTeos annonce ses priorités stratégiques et ses étapes clés prévues pour 2025
11/01/2025
- Plusieurs extractions de données cliniques issues du programme TIGIT attendues en 2025, portant sur plus de 400 patients issus de deux essais de Phase II et d’un essai de Phase I/II évaluant l’association belrestotug [...]
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/01/2025
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]
Matinas BioPharma Receives NYSE Noncompliance Notice
10/01/2025
BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has [...]
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/01/2025
Craig Swandal, experienced medical device manufacturing executive, joins leadership team ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and [...]
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/01/2025
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
10/01/2025
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]

Pages